N/A N=1 Esophageal Fully Covered Metal Stents in Caustic Strictures Study
Refractory Benign Esophageal Strictures Caused by Caustic Ingestion
Primary: Clinical Success — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
N/A N=18 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Refractory Anastomotic Esophageal Strictures
Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159
Phase 2 N=90 Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
Esophageal Stricture
Primary: Dysplasia in Barrett Esophagus (BE) — 4; 4; 3; 23 Participants — p=0.992
N/A N=112 Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures
Common Bile Duct Stricture
Primary: Early Clinical Success — 50; 41 Participants
N/A N=98 Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
Esophageal Cancer · Esophageal Stenosis
Primary: Number of Participants With Recurrent Dysphagia. — 11; 9 Participants
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
Phase 2 N=45 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
Barretts Esophagus With Dysplasia
Primary: Percentage of Patients With Successful Eradication — 45.5; 38.1; 36.4; 19.04 percentage of participants
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
N/A N=18 Cryo Balloon for Residual Barrett's Esophagus
Barrett's Esophagus
Primary: Eradication of Barrett's Esophagus — 2 Participants
N/A N=102 Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years
Barrett Esophagus
Primary: Percentage of Participants With Histological Clearance of Barrett's Metaplasia — 100; 20; 78; 82 Percent of Participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
N/A N=53 Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium
Barrett's Esophagus · Esophageal Squamous Dysplasia · Esophageal Cancer
Primary: Number of Participants With Complete Eradication of Esophageal Dysplasia — 51 Participants
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
N/A N=175 Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation
Primary: Incidence of Esophageal Injury as Assessed by Endoscopy — 1; 12; 4; 0 participants
N/A N=93 Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
Phase 2 N=78 Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
N/A N=30 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX
Esophageal Cancer
Primary: Anastomotic Leak Rate After Esophagectomy
N/A N=95 Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Laryngopharyngeal Reflux
Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05
Phase 3 N=187 WallFlex Biliary Fully Covered (FC) Benign Stricture Study
Biliary Stricture
Primary: Stent Removability — 132 Participants
N/A N=23 Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction
Biliary Stricture
Primary: Count of Participants With Stent Patency at 90 Days — 22 Participants
N/A N=138 Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
Barrett's Esophagus
Primary: Cytosponge Acceptability by Number of Participants — 46; 81; 2; 6 Participants
N/A N=23 Evaluation of the Use of Metal Stents as Part of the Treatment of Benign Biliary Strictures
Benign Biliary Strictures
Primary: Short Term Success Rate in the Resolution of Biliary Strictures — 22; 14; 3; 5 participants
N/A N=6 Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe
Barrett's Esophagus
Primary: Number of Participants With Tolerability of the Procedure — 6 Participants
N/A N=47 Esophageal Deviation in Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge…
Phase 4 N=30 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
Inflammation · Barrett's Esophagus
Primary: Change in Inflammation Biomarker Tissue PGE2 Level — 1.35; -0.02; 1.19; -0.06 nanograms/gram of tissue — p=0.30
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 4 N=20 Esophageal Food Impaction
Esophageal Food Bolus Obstruction
Primary: Patients Condition at Discharge — 2; 15 Participants
N/A N=7 Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Esophageal Cancer
Primary: Dose of Radiation Delivered to 90% of Tumor Volume (D90) — 105.5 percentage of Prescription dose
N/A N=44 An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Gastroesophageal Reflux Disease
Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants